Sugi Predict

Sugi Predict / Compounds / SCHEMBL3611200

SCHEMBL3611200

SCHEMBL3611200

Cc1ccccc1[C@H](N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRM1 Q13255 4/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ CYP1A2 P05177 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ ESR1 P03372 1/20 0.48
▸ ACP3 P15309 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP3A4 P08684 1/20 0.42
▸ SLC1A3 P43003 1/20 0.41
▸ SLC1A2 P43004 1/20 0.41
▸ SLC1A1 P43005 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611197 1.00 GRM1 (0.58) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL8749855 1.00 GRM1 (0.58) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL29748155 1.00 GRM1 (0.58) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL29747857 1.00 GRM1 (0.58) GRM1MEN1CYP1A2KMT2ATDP1
Hydrochloric Acid SCHEMBL30405940 0.98 GRM1 (0.56) GRM1MEN1CYP1A2KMT2ATDP1
Hydrochloric Acid SCHEMBL3820573 0.98 GRM1 (0.56) GRM1MEN1CYP1A2KMT2ATDP1
Glycine SCHEMBL8009728 0.91 GRM1 (0.50) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL24044801 0.84 MEN1 (0.48) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL25660557 0.84 GRM1 (0.53) GRM1MEN1CYP1A2KMT2ATDP1
SCHEMBL1115084 0.83 ESR1 (0.48) GRM1MEN1CYP1A2KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170137468-A1 MODULATION OF COMPLEMENT ACTIVITY UCB HOLDINGS, INC. 2017-05-18 — — US claimed
EP-3154561-A2 MODULATION OF COMPLEMENT ACTIVITY RA Pharmaceuticals, Inc. (US) 2017-04-19 — — EP claimed
WO-2015191951-A2 MODULATION OF COMPLEMENT ACTIVITY RA PHARMACEUTICALS, INC. (US) 2015-12-17 — — WO claimed
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 — — US disclosed
US-20240156896-A1 Modulators of Complement Activity UCB HOLDINGS, INC. 2024-05-16 — — US disclosed
US-11965040-B2 Modulation of complement activity RA PHARMACEUTICALS, INC. (US) 2024-04-23 — — US disclosed
EP-3980047-B1 INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS RA PHARMACEUTICALS INC (US) 2024-02-14 — — EP disclosed
US-11752190-B2 Modulators of complement activity RA PHARMACEUTICALS, INC. (US) 2023-09-12 — — US disclosed
US-11723949-B2 Modulators of complement activity RA PHARMACEUTICALS, INC. (US) 2023-08-15 — — US disclosed
EP-4223317-A2 MODULATION OF COMPLEMENT ACTIVITY RA Pharmaceuticals, Inc. (US) 2023-08-09 — — EP disclosed
EP-4218790-A1 MODULATORS OF COMPLEMENT ACTIVITY Ra Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
WO-2013134079-A1 OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. (US) 2013-09-12 — — WO disclosed
WO-2013134079-A1 OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. (US) 2013-09-12 — — WO disclosed
US-20120202794-A1 COMPOUNDS PHARMASSET, INC. (US) 2012-08-09 — — US disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 — — US disclosed
WO-2012103113-A1 PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C GILEAD PHARMASSET, LLC (US) 2012-08-02 — — WO disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 — — US disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 — — EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 — — US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R GRM1 236/4885MEN1 1746/4885CYP1A2 252/4885
US-20120202794-A1 COMPOUNDS HAVCR2, MAVS, GOT2 GRM1 3671/4885MEN1 4868/4885CYP1A2 820/4885
US-20170137468-A1 MODULATION OF COMPLEMENT ACTIVITY C5, C3AR1, CFH GRM1 2330/4885MEN1 1304/4885CYP1A2 4529/4885
US-11723949-B2 Modulators of complement activity C1QBP, C5, C3AR1 GRM1 2946/4885MEN1 571/4885CYP1A2 4773/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R GRM1 252/4885MEN1 2373/4885CYP1A2 265/4885
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN GRM1 1824/4885MEN1 1933/4885CYP1A2 4145/4885
US-11752190-B2 Modulators of complement activity C3AR1, C1QBP, C5AR1 GRM1 2396/4885MEN1 565/4885CYP1A2 4810/4885
US-20240156896-A1 Modulators of Complement Activity C3AR1, C1QBP, C5AR1 GRM1 2339/4885MEN1 480/4885CYP1A2 4798/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R GRM1 236/4885MEN1 1746/4885CYP1A2 252/4885
US-11965040-B2 Modulation of complement activity C5, C3AR1, CFH GRM1 2330/4885MEN1 1304/4885CYP1A2 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.